Clinical trials: Botulinum toxin type A
Esthetic Outcome of Injection of Botulinum Toxin Type-A in Cleft Lip Repair
Evaluation of the Effect of Botulinum Toxin Type-A Injection Prior to Surgical Correction of Complete Unilateral Cleft Lip Repair by Modified Millard Cheiloplasty
Evaluation of the effect of botulinum toxin type-A injection prior to surgical correction of complete unilateral cleftlip repair by modified millard cheiloplasty
- Trial name
- NCT03047499
- Testing
- Botulinum toxin type A
- Where
- Egypt
- Volunteers
- 2 people
- Sponsor
- Mostafa Khairy
Benign Masseteric Hypertrophy
DWP450 Treatment in Subjects With Benign Masseteric Hypertrophy
This study is A Randomized, Double-blind, Placebo-controlled, Phase II Optimal Dose-finding Study to Determine the Safety and Efficacy of DWP450 in Subjects with Benign Masseteric Hypertrophy
- Trial name
- NCT03369990
- Testing
- Botulinum toxin type A
- Volunteers
- 98 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Spasticity of the Upper and Lower Limb Due to Cerebral Causes
Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm
The purpose of this study is to determine whether injections with increasing doses (up to 800 units) of Botulinum toxin type A into muscles of the leg and/or arm are safe and effective in treating patients with spasticity on one…
- Trial name
- NCT01603459
- Testing
- IncobotulinumtoxinA
- Where
- 33 sites in United States, Canada and 6 more
- Volunteers
- 155 people
- Sponsor
- Merz Pharmaceuticals GmbH
Glabellar Frown Lines
A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001
The primary objective is to demonstrate the safety and efficacy of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in the treatment of moderate to severe glabellar lines associated with corrugator and/or procerus muscle…
- Trial name
- NCT02334423
- Testing
- Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
- Where
- United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Overactive Bladder Syndrome
Xeomin vs Botox for Treatment of Overactive Bladder Syndrome
Purpose: Multiple formulations and brands of botulinum toxin exist on the market today. Only OnabotulinumtoxinA (BOTOX®) is currently FDA approved for treatment of overactive bladder.
- Trial name
- NCT06034288
- Testing
- Xeomin 100 UNT Injection, Botox 100 UNT Injection
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Walter Reed National Military Medical Center
Mood
Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction
Botox treatment into the upper one third of the face (glabella, forehead lines and/or lateral canthal lines) to analyze mood and self -appearance satisfaction in a Post Covid period on non-naïve Botox patients
- Trial name
- NCT04439825
- Testing
- Botulinum Neurotoxin
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- DeNova Research
Chronic Anal Fissure
Low Versus High Dose OnabotulinumtoxinA for Chronic Anal Fissure
This prospective single-center cohort study describes short-term and one-year clinical outcomes of two routine doses of OnabotulinumtoxinA (20 units versus 50 units) for chronic anal fissure refractory to conservative therapy.
- Trial name
- NCT07543315
- Testing
- OnabotulinumtoxinA
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Tanta University
Spasticity, Stroke
A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity
Purpose: This study is a Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb(wrist, finger…
- Trial name
- NCT01945684
- Testing
- Botulinum toxin type A
- Where
- South Korea
- Volunteers
- 197 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Cervical Dystonia
Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)
Phase 3, open-label, multi-center trial to evaluate the long-term safety, efficacy, and immunogenicity of up to four continuous treatment cycles of daxibotulinumtoxinA (DAXI) for injection.
- Trial name
- ASPEN-OLS (NCT03617367)
- Testing
- daxibotulinumtoxinA for injection
- Where
- 65 sites in United States, Austria and 7 more
- Volunteers
- 357 people
- Sponsor
- Revance Therapeutics, Inc.
Masseter Muscle Prominence
BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence
This study is designed to evaluate the safety and effectiveness of administering BOTOX for the treatment of Masseter Muscle Prominence (MMP) in adults.
- Trial name
- NCT04073303
- Testing
- Botulinum Toxin Type A
- Where
- 21 sites in Canada, China and 1 more
- Volunteers
- 377 people
- Sponsor
- AbbVie
Cerebral Palsy
Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?
The purpose of the study is to compare the effectiveness of 3 doses of Dysport (5, 10 or 15 Units/Kg/hip) in the management of chronic bilateral hip pain due to cerebral palsy in children/young people.
- Trial name
- NCT00455637
- Testing
- Botulinum toxin type A
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Ipsen
Hemifacial Microsomia, Facial Nerve Paralysis
Treatment for "Asymmetric Crying Facies"
This study focuses on children with hemifacial microsomia (HFM), a common congenital craniofacial deformity caused by abnormal development of the first and second branchial arches.
- Trial name
- NCT07802639
- Testing
- Botulinium toxin type A injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xiaolei Jin
Temporomandibular Joint Disorder Bilateral
Efficacy of Botulinum Toxin in Temporomandibular Disorders
Temporomandibular disorders (TMDs) represent a multifactorial pathological group that gives rise to a varied and complex symptomatology that includes decreased jaw movement, muscle and joint pain, joint crepitation and limitation…
- Trial name
- TMD (NCT05651256)
- Testing
- Botulinum toxin type A injection
- Where
- Spain
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Salamanca
Sun-induced Wrinkles
Safety and Efficacy of the Full Face Applications of Variable Doses of a Commercial Botulinum Toxin Type a (Dysport®)
This is an open-label and phase IV study of full face injections of variable doses of botulinum toxin type A (BT-A). As it is an open-label and not blind study, both investigator and subjects will know the injection local and…
- Trial name
- NCT01032954
- Testing
- Botulinum toxin
- Where
- Brazil
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Hexsel Dermatology Clinic
Vaginismus
Botox Injection for Treatment of Vaginismus
The use of Botox injections intravaginally and progressive dilation under anesthesia has been shown to cure vaginismus. This study expands the use of Botox injections to include progressive dilation, post procedure supervised…
- Trial name
- NCT01352546
- Testing
- BOTOX
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Plastic Surgery Professional Association
High Tone Pelvic Floor Dysfunction
EMG Guided Botulinum Toxin Type A Injections for Refractory High Tone Pelvic Floor Dysfunction
This is a prospective, pilot, longitudinal study to evaluate the use of EMG guidance for Botox A injection for chronic pelvic pain and HTPFD.
- Trial name
- BTXA EMG (NCT01323829)
- Testing
- EMG Guidance of Injection
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Pelvic and Sexual Health Institute
Overactive Bladder, Incontinence, Daytime Urinary
Botulinum Neurotoxin Type A (BoNT-A) in Paediatric Non-neurogenic Therapy Resistant Overactive Bladder (OAB)
A non-intervention cohort study on the use of Botulinum Neurotoxin Type A (BoNT-A) in Paediatric Non-neurogenic Therapy Resistant Overactive Bladder (OAB). Primary endpoint was the reduction of urinary incontinence.
- Conditions
- Overactive Bladder, Incontinence, Daytime Urinary, Incontinence, Nighttime Urinary
- Trial name
- NCT06569342
- Testing
- Intradetrusor BoNT-A
- Where
- Denmark
- Volunteers
- 43 people
- Sponsor
- University of Aarhus
Fissure in Ano
Complex Treatment of a Chronic Anal Fissure
This study is aimed at studying the efficacy and safety of treating chronic anal fissure with botulinum toxin versus lateral subcutaneous sphincterotomy.
- Trial name
- NCT03855046
- Testing
- IncobotulinumtoxinA 50 U Intramuscular Powder for Solution, Lateral subcutaneous sphincterotomy.
- Where
- 7 sites in Russia
- Volunteers
- 340 people
- Sponsor
- State Scientific Centre of Coloproctology, Russian Federation
Upper Facial Rhytides, Crow's Feet Lines
BOTOX® in the Treatment of Upper Facial Lines in Japan
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) for the treatment of upper facial lines (Crow's Feet Lines and Frown Lines).
- Conditions
- Upper Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Frown Lines
- Trial name
- NCT01797094
- Testing
- botulinum toxin Type A (44U), botulinum toxin Type A (32U)
- Where
- Japan
- Volunteers
- 101 people
- Sponsor
- Allergan
Facial Rhytides, Crow's Feet Lines
Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)
A study to evaluate patient satisfaction, aesthetic and psychological impact of combined treatment with BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS XC, JUVÉDERM® VOLUMA® XC, and LATISSE®…
- Conditions
- Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Nasolabial Fold
- Trial name
- NCT02176356
- Testing
- onabotulinumtoxinA, bimatoprost ophthalmic solution 0.03%, JUVÉDERM® ULTRA XC
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Allergan
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.